Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...

By Taren Grom • March 15, 2023

Targeting the new ‘Golden Girls’

With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.

By Taren Grom • March 8, 2023

Multimillion-dollar therapies are changing how payers foot the bill

With more gene therapies headed to market, novel payment methods are emerging from regulators and academia. 

By Meagan Parrish • Feb. 28, 2023

Why patient care is a public affair

The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.

By Taren Grom • Feb. 23, 2023

Woman of the Week: Bristol Myers Squibb’s Ester Banque

The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

By Taren Grom • Feb. 15, 2023

For Complement’s CEO, storytelling could be just as critical as data

Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.

By Alexandra Pecci • Feb. 14, 2023

Brian Fox is bringing ‘fresh eyes’ to ad agency Klick

Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.

By Karissa Waddick • Feb. 13, 2023

Survey results: Social influences HCP perceptions and prescriptions

Build social strategies into marketing plans to reach HCPs with sharply focused messaging.

Feb. 13, 2023

Antitrust watchdogs have pharma in their sights, and the landscape is getting thornier

The FTC and DOJ are heightening antitrust enforcement, and pharma deals are a prime target.

By Karissa Waddick • Feb. 2, 2023

Woman of the Week: Bayer’s Dr. Yesmean Wahdan

The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

By Taren Grom • Feb. 1, 2023

Vaxxinity eyes global COVID-19 vaccine market with ‘next-gen’ booster

The biotech aims to complete rolling submissions with regulators in the U.K. and Australia in the first half of 2023.

By Alexandra Pecci • Jan. 31, 2023

Patients are using social media — clinical trial experts can learn from that

Why an alliance of industry leaders is exploring the potential of social media as a treasure trove of real-world patient experience insights. 

By Karissa Waddick • Jan. 30, 2023

Weight loss drugs: the promise and pitfalls

GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.

By Kelly Bilodeau • Jan. 30, 2023

Boost returns from social strategies with new channels and tactics

Emerging channels offer new ways to reach key targets and improve campaign ROI.

Jan. 30, 2023

With Twitter in flux, pharma is turning to alternative social spaces

Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging.

By Karissa Waddick • Jan. 26, 2023

Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

By Meagan Parrish • Jan. 26, 2023

Woman of the Week: Dr. Lauren Lazar

As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

By Taren Grom • Jan. 25, 2023

AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships

A longtime leader in the respiratory space, AstraZeneca has hammered another stake in the ground with its newest asthma treatment, Airsupra.

By Michael Gibney • Jan. 24, 2023

Drug price negotiations: 5 key dates to watch

As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.

By Kelly Bilodeau • Jan. 23, 2023

Already on a roll in oncology, Astellas hunts for big wins in other areas

With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

By Karissa Waddick • Jan. 23, 2023

Tactics for growing your walled garden presence

Cultivate relationships with HCPs in gated social platforms with content that will thrive.

Jan. 23, 2023

FDA’s 2022 drug approvals fall short of recent norms

The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.

By Alexandra Pecci • Jan. 19, 2023

After ‘limping along,’ Novavax sees a path forward

With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.

By Meagan Parrish • Jan. 18, 2023

Can pharma quit Twitter? Social strategy evolves as Musk changes the platform

A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.

By Karissa Waddick • Dec. 16, 2022

Woman of the Week: Exelixis’ Dr. Vicki Goodman

With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

By Taren Grom • Dec. 14, 2022